Gastroenterology Today Summer 2021
Gastroenterology Today Summer 2021
Gastroenterology Today Summer 2021
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
IDENTIFYING ATROPHIC<br />
GASTRITIS WITH THE AID<br />
OF GASTROPANEL ® FROM<br />
BIOHIT HEALTHCARE<br />
A first-line test to prioritise<br />
gastroscopy referrals<br />
FEATURE<br />
BIOHIT HealthCare’s GastroPanel is a simple and effective<br />
first-line test to diagnose Helicobacter pylori (H. pylori) and<br />
atrophic gastritis in patients presenting with dyspepsia and<br />
upper abdominal symptoms. Where endoscopy resources are<br />
overstretched and capacity is restricted, GastroPanel helps by<br />
identifying those at greatest risk in a primary care setting prior<br />
to referral.<br />
Chronic H. pylori infection is the primary cause of atrophic<br />
gastritis – a condition of the gastric mucosa considered to be<br />
the greatest independent risk factor for developing gastric<br />
cancer – and current guidance recommends that individuals<br />
with extensive gastric atrophy undergo regular endoscopic<br />
surveillance to closely monitor their disease progression.<br />
Early detection of those individuals with a significant risk<br />
of developing gastric cancer is the key to effective patient<br />
management, helping to reduce unnecessary referrals, and<br />
improving survival rates through earlier diagnoses.<br />
GastroPanel comprises reliable and automatable assays<br />
for four stomach-specific biomarkers, enabling thorough<br />
and objective investigation of the whole gastric mucosa, and<br />
offering clinicians more confidence in their diagnoses. The<br />
highly specific IgG antibody test for identifying H. pylori is<br />
combined with the analysis of pepsinogen I, pepsinogen II and<br />
gastrin-17 to establish the structure and function of the entire<br />
gastric mucosa. Implementing this first-line diagnostic test<br />
can help to relieve the burden on overstretched gastroscopy<br />
services, streamlining referrals for high-risk patients and<br />
effectively ruling out gastrointestinal (GI) diseases for others.<br />
This patient-friendly blood test can help transform the<br />
referral pathway for upper GI investigations by aligning clinical<br />
resources and identifying those in need of endoscopy at an<br />
early stage, making it ideal for dyspepsia diagnosis.<br />
GastroPanel is a simple, effective and low cost blood test for<br />
assessment of the structure and function of the stomach in<br />
patients with dyspepsia, helping the effective diagnosis of<br />
chronic atrophic gastritis, acid output disorders, and other<br />
diseases of the gastric mucosa resulting from a H. pylori<br />
infection. It reveals the health and status of the gastric<br />
mucosa, and provides information about the associated risks.<br />
This enables the implementation of appropriate and effective<br />
treatment plans, including eradication therapy, risk-based<br />
referral for further investigation, and antacid prescription.<br />
Key advantages of GastroPanel:<br />
• Reliable detection of healthy stomach mucosa, atrophic<br />
gastritis, acid dysregulation, and H. pylori infection<br />
• Patient and provider-friendly blood test for primary care<br />
settings<br />
• Guides patient management and referral to reduce waiting<br />
times<br />
• Helps to identify patients most at risk of gastric cancer prior<br />
to endoscopy<br />
• Fast turnaround time<br />
To find out more about how GastroPanel can help diagnose gastric cancer<br />
risk in a clinical setting, visit www.biohithealthcare.co.uk/GPblog<br />
GASTROENTEROLOGY TODAY - SUMMER <strong>2021</strong><br />
BIOHIT HealthCare Ltd<br />
Pioneer House, Pioneer Business Park, North Road,<br />
Ellesmere Port, CHESHIRE, United Kingdom CH65 1AD<br />
Tel. +44 151 550 4 550<br />
info@biohithealthcare.co.uk<br />
www.biohithealthcare.co.uk<br />
11